207 related articles for article (PubMed ID: 21901246)
1. Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer.
Miyaki Y; Suzuki K; Koizumi K; Kato T; Saito M; Kamiyama H; Maeda T; Shibata K; Shiya N; Konishi F
Int J Oncol; 2012 Jan; 40(1):217-26. PubMed ID: 21901246
[TBL] [Abstract][Full Text] [Related]
2. Effect of combined therapy with low-dose 5-aza-2'-deoxycytidine and irinotecan on colon cancer cell line HCT-15.
Ishiguro M; Iida S; Uetake H; Morita S; Makino H; Kato K; Takagi Y; Enomoto M; Sugihara K
Ann Surg Oncol; 2007 May; 14(5):1752-62. PubMed ID: 17195906
[TBL] [Abstract][Full Text] [Related]
3. Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
Ikehata M; Ogawa M; Yamada Y; Tanaka S; Ueda K; Iwakawa S
Biol Pharm Bull; 2014; 37(1):67-73. PubMed ID: 24172061
[TBL] [Abstract][Full Text] [Related]
4. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
[TBL] [Abstract][Full Text] [Related]
5. WNT5A Promoter Methylation Is Associated with Better Responses and Longer Progression-Free Survival in Colorectal Cancer Patients Treated with 5-Fluorouracil-Based Chemotherapy.
Jiang G; Lin J; Wang W; Sun M; Chen K; Wang F
Genet Test Mol Biomarkers; 2017 Feb; 21(2):74-79. PubMed ID: 28051879
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
[TBL] [Abstract][Full Text] [Related]
7. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E
J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer.
Kaneko M; Kotake M; Bando H; Yamada T; Takemura H; Minamoto T
BMC Cancer; 2016 Dec; 16(1):945. PubMed ID: 27955637
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance.
Shin YK; Yoo BC; Hong YS; Chang HJ; Jung KH; Jeong SY; Park JG
Electrophoresis; 2009 Jun; 30(12):2182-92. PubMed ID: 19582719
[TBL] [Abstract][Full Text] [Related]
10. Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in p53 mutant human colon cancer.
Tanaka K; Inoue Y; Hiro J; Yoshiyama S; Toiyama Y; Eguchi T; Miki C; Kusunoki M
J Exp Clin Cancer Res; 2007 Jun; 26(2):241-51. PubMed ID: 17725105
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
Asia Pac J Clin Oncol; 2011 Mar; 7(1):82-7. PubMed ID: 21332655
[TBL] [Abstract][Full Text] [Related]
12. [A case of irinotecan-resistant colon cancer responding to chronotherapy with oxaliplatin, 5-FU, l-LV].
Sagawa T; Tsuji Y; Takayanagi N; Hirayama Y; Sakamaki S; Chiba H; Iyama S; Oku T; Sato Y; Takahashi M; Takayama T; Niitsu Y
Gan To Kagaku Ryoho; 2003 Apr; 30(4):537-43. PubMed ID: 12722689
[TBL] [Abstract][Full Text] [Related]
13. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
Boyer J; McLean EG; Aroori S; Wilson P; McCulla A; Carey PD; Longley DB; Johnston PG
Clin Cancer Res; 2004 Mar; 10(6):2158-67. PubMed ID: 15041737
[TBL] [Abstract][Full Text] [Related]
14. The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.
Scartozzi M; Sobrero A; Gasparini G; Berardi R; Catalano V; Graziano F; Barni S; Zaniboni A; Beretta GD; Labianca R; Cascinu S;
Oncology; 2005; 68(2-3):212-6. PubMed ID: 16015036
[TBL] [Abstract][Full Text] [Related]
15. Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells.
Motwani M; Sirotnak FM; She Y; Commes T; Schwartz GK
Cancer Res; 2002 Jul; 62(14):3950-5. PubMed ID: 12124325
[TBL] [Abstract][Full Text] [Related]
16. Review of the role of CPT-11 in the treatment of colorectal cancer.
Rougier P; Mitry E
Clin Colorectal Cancer; 2001 Aug; 1(2):87-94. PubMed ID: 12445366
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine as third line therapy in patients with advanced colorectal cancer.
Gubanski M; Naucler G; Almerud A; Lideståhl A; Lind PA
Acta Oncol; 2005; 44(3):236-9. PubMed ID: 16076695
[TBL] [Abstract][Full Text] [Related]
18. A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.
Viel E; Demarchi MF; Chaigneau L; Nguyen T; Legat C; Stein U; Thiery-Vuillemin A; Limat S; Pivot X; Borg C
Am J Clin Oncol; 2008 Feb; 31(1):89-94. PubMed ID: 18376234
[TBL] [Abstract][Full Text] [Related]
19. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
